Efficacy

Opdivo (Nivolumab) Efficacy in Lymphoma

Opdivo, also known by its generic name Nivolumab, is an immunotherapy drug that has been studied for its efficacy in treating certain types of lymphoma. It is a programmed death receptor-1 (PD-1) blocking antibody that has shown promise in the treatment of classical Hodgkin Lymphoma (cHL), particularly after the failure of autologous stem cell transplant (ASCT) or after at least two types of treatment in patients who are not ASCT candidates. Clinical trials have demonstrated that Opdivo can induce a significant response rate in patients with relapsed or refractory cHL, leading to its approval by regulatory agencies for this indication.

While the efficacy of Opdivo in non-Hodgkin lymphoma (NHL) is still under investigation, some studies suggest that it may provide benefits to patients with certain subtypes of NHL. The response rates in these studies vary depending on the subtype and the prior treatments the patients have received. However, it is important to note that the use of Opdivo for NHL may still be considered off-label, and its efficacy in this broader group of lymphoma patients requires further validation through clinical trials.

Zynlonta (Loncastuximab Tesirine-lpyl) Efficacy in Lymphoma

Zynlonta, with the generic name loncastuximab tesirine-lpyl, is a CD19-directed antibody and alkylating agent conjugate used for the treatment of certain types of B-cell lymphomas. It has shown efficacy in adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL), DLBCL arising from low-grade lymphoma, and other high-grade B-cell lymphomas. Clinical trials have demonstrated that Zynlonta can achieve objective response rates in a significant proportion of patients, with a subset achieving complete responses.

The approval of Zynlonta for these indications was based on the results of a multicenter, open-label, single-arm trial, where patients showed a marked response to the treatment. As a targeted therapy, Zynlonta represents a novel approach in the management of refractory or relapsed B-cell lymphomas, offering a new option for patients who have exhausted other treatment lines. Nevertheless, ongoing studies continue to evaluate its long-term efficacy and safety profile in a broader population of lymphoma patients.